Jack Hall, MD
Interventional Cardiology · Springfield, ILNPI 1558337857
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,525 of the $39,597 with a category attached, or 82.1%. Boston Scientific accounts for 96.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $20,959 and has fallen 99.3% since, to $155 in 2025.
Across 117 payments — averaging $338.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$38K
- Johnson & Johnson$238
- Abiomed$165
- Amgen$157
- Biotronik Inc.$150
- Abbott$134
- plus $687 from 13 others
What the payments were for
- Consulting fees$1,2003%
- Speaking & faculty fees$32,52582%
- Travel & lodging$3,5939%
- Food & beverage$2,1996%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 51 | $38,067 |
| Johnson & Johnson(2 entities) | 9 | $238 |
| Abiomed | 5 | $165 |
| Amgen | 9 | $157 |
| Biotronik Inc. | 8 | $150 |
| Abbott | 1 | $134 |
| W. L. Gore & Associates, Inc. | 1 | $128 |
| AbbVie | 6 | $102 |
| Cardiovascular Systems Inc. | 4 | $90 |
| E.r. Squibb & Sons, L.L.C. | 5 | $75 |
| Pfizer | 4 | $57 |
| Shockwave Medical, Inc | 3 | $54 |
| AstraZeneca | 4 | $52 |
| Penumbra, Inc. | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Medtronic | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR ACCESS$19,869
- CROSSBOSS$15,799
- GENERAL - THERAPIES$993
- GENERAL PAIN MANAGEMENT$546
- AMPLATZER TALISMAN$134
- GORE CARDIOFORM Septal Occluder$128
- ROTABLATOR$116
- XARELTO$109
How this compares
$39,597 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 18 | $294 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Springfield
- Tony de MartiniSpringfield$208K
- Shady HenienSpringfield$105K
- Donald YakelSpringfield$54K
- Krishna Rocha SinghSpringfield$25K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.